查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856589

強迫症治療市場按藥物類別、通路、藥物類型、給藥途徑、最終用戶和患者年齡層分類－2025-2032年全球預測

Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route Of Administration, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，強迫症藥物市場將成長至 19.1738 億美元，複合年成長率為 8.89%。

關鍵市場統計數據
基準年 2024 9.6971億美元
預計年份：2025年 1,054,510,000 美元
預測年份 2032 1,917,380,000 美元
複合年成長率 (%) 8.89%

一本簡明扼要的強迫症藥物治療臨床和商業性指南，將治療細節與市場策略要務結合。

強迫症藥物治療領域亟需為臨床治療、產品研發及市場進入等相關相關人員提供清晰簡潔的指導。本執行摘要首先聚焦於治療背景，強調強迫症持續存在的臨床複雜性、患者特徵的異質性，以及藥物治療與認知行為治療結合的重要作用。透過介紹實證治療路徑和現有藥物類別的多樣性，引言部分為深入分析市場動態、監管影響和供應鏈考量奠定了基礎。

引言部分從臨床框架出發，探討了商業性影響，並強調了整合策略思維的必要性，這種思維方式應充分考慮藥物類別、分銷管道和患者群體的多樣性。後續章節闡述了當前的行業趨勢、政策變化和市場細分訊息，旨在為高層決策提供依據。這種背景知識有助於讀者理解臨床實際情況如何轉化為商業性槓桿，使他們能夠基於數據做出關於產品組合優先事項、患者准入策略和夥伴關係機會的選擇。

詳細闡述了科學、監管和商業性力量的融合如何塑造強迫症藥物的研發路徑和上市策略。

強迫症的治療體係正因不斷發展的臨床證據、監管調整以及藥物研發和遞送技術的進步而改變。精準精神病學的最新進展和強迫症亞型表現型的精細化，提高了靶點識別的準確性，並重新激發了人們對現有抗憂鬱症和新型作用機制的興趣。同時，監管機構正透過明確適應性試驗設計路徑，並為存在高度未滿足需求的適應症提供快速核准流程，來調整研發時間表和投資策略。

在商業層面，數位療法和遠端保健的整合正在再形成患者就醫旅程中的各個環節，改變處方行為，並提升真實世界證據和上市後藥物安全檢測的重要性。供應鏈最佳化、策略性生產夥伴關係以及對可負擔性和支付方價值框架的日益關注，都成為重新定義市場准入和規模的新槓桿。總而言之，這些因素正迫使企業重新評估其研發組合，尋求差異化的製劑和給藥途徑，並採用更具協作性的商業化模式，以使臨床獲益與支付方和醫療服務提供者不斷變化的期望相契合。

對 2025 年美國關稅如何改變 OCD 製藥價值鏈的供應鏈、採購決策和價格談判進行全面分析。

美國關稅將於2025年實施，其累積影響正波及強迫症藥物價值鏈的多個環節，迫使相關人員重新評估供應韌性、成本結構和籌資策略。關稅帶來的投入成本壓力尤其影響原料藥和某些特殊輔料，迫使製造商評估替代供應商和生產地區，以便在確保產品品質的同時保護淨利率。同時，整個產業正朝著雙重採購和增加庫存緩衝的方向發展，以應對未來貿易政策的波動。

支付者、採購團隊和醫院處方醫生正在透過加強價格談判和探索合約前置作業時間。關稅也凸顯了透明成本模型和情境規劃的重要性，促使企業將貿易政策風險納入供應鏈決策，並尋求能夠吸收或抵銷關稅影響、同時保障病患用藥的策略聯盟。

透過整合策略性細分，將藥物類別、管道、劑型和患者群體與不同的商業性和臨床挑戰進行配對。

透過細緻的市場細分，我們可以發現影響強迫症藥物需求、使用和競爭壓力的差異化商業動態。依藥物類別分類，主要的抗憂鬱症類別－包括單胺氧化酵素抑制劑（MAOI）、 正腎上腺素再回收抑制劑（SNRI）、選擇性血清素再回收抑制劑（ SSRI）和三環抗憂鬱藥物（ TCAs）－各自展現出不同的療效和耐受性。 MAOI包括苯乙肼和反苯環丙胺；SNRIDesvenlafaxine、FluoxetineDuloxetine和文拉法辛；SSRI包括西酞普蘭、氟西汀、氟伏沙明、帕羅西汀和舍曲林；TCAs包括阿米替林、氯米帕明和丙咪嗪。這些治療上的細微差別會影響處方模式、藥物轉換行為和長期用藥依從性。

分銷管道動態涵蓋醫院藥房、線上藥房和零售藥房，每種管道滿足不同的患者用藥需求和報銷途徑，從而影響產品的商業化和支援方式。依藥物類型分類品牌藥和學名藥市場，會影響定價策略、生命週期管理方法和商業化投資。給藥途徑（例如口服與注射）會影響製劑優先順序、依從性支持需求和臨床給藥環境。終端使用者（例如診所、醫院和家庭）的分類反映了採購週期、醫療服務模式和病患教育需求的差異。最後，由於安全考量、給藥模式和監管文件的不同，將患者群體分類為成人和兒童群體，需要採取不同的臨床應用和市場滲透策略。

提供實用的區域資訊，解釋美洲、歐洲、中東和非洲以及亞太地區的市場動態如何需要不同的商業化和市場准入策略。

強迫症藥物的研發、報銷和交付方式在不同地區差異顯著，需要製定相應的策略。在美洲，准入框架、支付方的多樣性以及蓬勃發展的民營市場共同塑造了藥物商業化策略，並優先考慮證據的生成，以支持藥物納入醫保目錄和獲得醫保報銷。該地區強調以結果為導向的合約和真實世界證據，以證明藥物在各種醫療服務模式下的價值。

歐洲、中東和非洲的監管方式和報銷環境呈現出多元化的格局，在集中監管路徑、國家衛生技術評估要求以及新興市場限制等方面存在顯著差異。亞太地區正在快速推廣數位醫療模式，本土生產的學名藥和生物相似藥的作用日益增強。在所有地區，不斷發展的患者權益倡導、遠端醫療的普及以及對本地化生產的考量，都將導致市場准入和規模的差異化。

競爭考察和企業行動著重於創新、生命週期管理和夥伴關係策略，這些因素共同塑造了強迫症治療產品組合。

強迫症治療領域的競爭和企業活動體現了創新投資、生命週期管理以及旨在解決准入和差異化問題的夥伴關係的融合。各公司正加大對後期臨床項目的投入，力求在療效和耐受性方面超越現有標準療法，同時透過改進製劑、緩釋性和組合藥物療法來最佳化產品組合。隨著各公司尋求互補的非藥物解決方案以改善整體療效，與學術中心和數位醫療供應商的研究合作也日益普遍。

同時，學名藥的上市和專利到期藥物的出現給定價和報銷帶來了壓力，迫使原廠藥企業透過療效數據和配套服務來強調品牌價值。策略許可、共同促銷和本地化生產協議正被用於促進分銷和降低供應風險。投資人對研發效率的嚴格審查促使企業更加重視那些具有明確臨床差異化和監管獎勵的項目。整體而言，企業策略正趨向於在創新、成本控制和夥伴關係之間取得平衡，以保持競爭力並滿足支付方和患者的期望。

為企業主管提供切實可行的建議，以增強強迫症藥物的供應韌性、證據產生和價值主導商業化。

致力於鞏固自身在強迫症治療領域地位的產業領導者應優先採取一系列切實有效、影響深遠的舉措，以增強自身韌性並實現商業性差異化。首先，透過在臨床試驗設計早期階段納入健康經濟學和結果研究，使臨床開發方案與支付方的證據要求相符，將縮短獲得處方箋的路徑。同時，透過地理多元化和策略性生產協議來強化供應鏈，將降低貿易政策衝擊帶來的風險，並確保供應的持續性。

領導者也應透過投資數位化和病患支援服務來強化產品價值提案，從而提高病患依從性和實際療效。與行為健康服務提供者和遠端醫療平台合作，可以擴大服務覆蓋範圍，惠及服務不足的患者群體，並創建整合式醫療解決方案。最後，採用動態定價和合約框架，以反映在不同醫療環境中提供的價值，並積極監控監管和報銷政策的變化，靈活應對。透過採取這些協調一致的舉措，企業既能提供具有臨床意義的創新，又能保障醫療服務的可近性和商業性可行性。

我們採用透明的多方法研究途徑，將主要相關人員調查與系統性的二手證據相結合，從而提供可靠、可重複的策略見解。

本執行分析所依據的研究結合了第一手資料和第二手資料，以確保提供可靠且多角度驗證的洞見。第一手資料包括對臨床醫生、負責人、採購負責人和生產專家進行結構化訪談，以了解醫療機構的實踐做法、處方行為和獲取途徑的限制。第二手資料包括對同行評審的臨床文獻、監管指導文件、臨床試驗註冊庫和公開的安全報告進行系統性回顧，以檢驗治療趨勢和證據缺口。

分析方法酌情結合了定性綜合和定量趨勢分析，包括對監管申請、專利狀態和供應鏈事件歷史進行時間序列分析。專家諮詢和基於情境的敏感性檢驗被用於交叉檢驗有關供應風險和政策影響的假設。整個過程始終遵循倫理原則並專注於資料來源，並著重於方法論的透明度和可重複性，以使相關人員能夠充滿信心地做出決策。

執行綜合分析強調，需要整合臨床差異化、供應彈性以及以患者為中心的策略，才能使強迫症藥物持續療效。

總之，當代強迫症治療領域面臨臨床、監管和商業方面的多重壓力與機會。臨床認知的進步和輔助性數位化干涉措施的出現，為改善病患療效鋪平了道路；而貿易政策的轉變和學名藥競爭的加劇，正在重塑成本和供應格局。因此，決策者必須將實證醫學、供應鏈韌性和以病人為中心的支援服務整合到一個連貫的策略中，該策略既要反映當地市場實際情況，又要滿足支付方的期望。

透過優先考慮差異化的臨床價值、增強生產和採購的靈活性，以及​​利用夥伴關係關係拓展醫療服務範圍，相關人員可以在應對政策變化和競爭壓力的同時，改善病患就醫途徑。這些措施的綜合效果將決定哪些機構能夠將科學進步永續地轉化為廣泛的臨床影響和持久的商業性成功。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 迷幻藥輔助性治療（如裸蓋菇素）在治療難治性強迫症的臨床試驗中興起
  • 擴大使用數位療法和遠距精神病學平台進行遠距強迫症症狀管理
  • 利用基因生物標記預測強迫症藥物療效的精準醫療策略的進展
  • 麩胺酸調節劑作為一種新型作用機制，在強迫症藥物研發中越來越受到重視。
  • 擴大真實世界臨床試驗和病患報告結果數據，以影響強迫症藥物的報銷決策
  • 針對嚴重強迫症治療候選藥物的監管進展，可望獲得快速通道資格和孤兒藥認定
  • 價格競爭壓力將推動現有 SSRI 類藥物的學名藥和生物相似藥的研發。
  • 增加強迫症聯合治療試驗的投資，將藥物治療與認知行為介入結合。
  • 將亞太地區和拉丁美洲等新興市場拓展為強迫症藥物的新成長途徑
  • 針對兒童和青少年強迫症治療的研究將加速兒科專用製劑的開發和核准。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的強迫症治療市場

  • MAOI
    • 苯乙肼
    • 反式環丙胺
  • SNRI
    • Desvenlafaxine
    • Duloxetine
    • 文拉法辛
  • SSRI
    • 西酞普蘭
    • Fluoxetine
    • 氟伏沙明
    • 帕羅西汀
    • 舍曲林
  • TCAs
    • 阿米替林
    • 氯米帕明
    • 丙咪嗪

9. 強迫症治療藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 強迫症治療藥物市場（依藥物類型分類）

  • 品牌
  • 非專利的

第11章 強迫症治療市場（依給藥途徑分類）

  • 口服
  • 腸外

第12章 強迫症治療藥物市場（依最終使用者分類）

  • 診所
  • 醫院
  • 家

第13章 依患者年齡層分類的強迫症治療藥物市場

  • 成人版
  • 孩子們

第14章 各地區強迫症治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 強迫症治療藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國強迫症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Johnson & Johnson
Product Code: MRR-742BD51822E2

The Obsessive-Compulsive Disorder Drugs Market is projected to grow by USD 1,917.38 million at a CAGR of 8.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 969.71 million
Estimated Year [2025] USD 1,054.51 million
Forecast Year [2032] USD 1,917.38 million
CAGR (%) 8.89%

Concise clinical and commercial orientation to obsessive-compulsive disorder pharmacotherapy that aligns therapeutic nuance with strategic market imperatives

The landscape of pharmacological interventions for obsessive-compulsive disorder demands a clear, concise orientation for stakeholders operating at the intersection of clinical care, product development, and market access. This executive summary opens with a focused introduction to the therapeutic context, highlighting the enduring clinical complexity of OCD, the heterogeneity of patient presentations, and the critical role that pharmacotherapy plays alongside cognitive and behavioral approaches. By emphasizing evidence-based treatment pathways and the diversity of available drug classes, the introduction sets the stage for deeper analysis of market dynamics, regulatory influences, and supply chain considerations.

Transitioning from clinical framing to commercial implications, the introduction underscores the need for integrated strategic thinking that accounts for variations in drug classes, distribution channels, and patient demographics. It clarifies that the subsequent sections synthesize current industry trends, policy shifts, and segmentation intelligence to inform senior-level decisions. This contextual foundation ensures readers appreciate how clinical realities map onto commercial levers, enabling data-driven choices about portfolio prioritization, patient access strategies, and partnership opportunities.

Detailed account of converging scientific, regulatory, and commercial forces reshaping development pathways and market access strategies for OCD pharmacotherapies

The therapeutic ecosystem for obsessive-compulsive disorder is undergoing transformative shifts driven by evolving clinical evidence, regulatory recalibrations, and technological advances in drug development and delivery. Recent progress in precision psychiatry and more refined phenotyping of OCD subtypes has sharpened target identification and reinvigorated interest in both established antidepressant classes and novel mechanisms of action. Concurrently, regulators are clarifying pathways for adaptive trial designs and expedited review for high-unmet-need indications, which is altering development timelines and investment calculus.

On the commercial front, digital therapeutics and telehealth integration are reshaping patient journey touchpoints and altering prescribing behavior, increasing the importance of real-world evidence and post-market pharmacovigilance. Supply chain optimization, strategic manufacturing partnerships, and an intensifying focus on affordability and payer value frameworks represent additional levers redefining market entry and scale. Collectively, these forces are prompting companies to re-evaluate R&D portfolios, pursue differentiated formulations and delivery routes, and adopt more collaborative commercialization models that align clinical benefit with payers' and providers' evolving expectations.

Comprehensive analysis of how the 2025 United States tariff measures are reshaping supply chains, sourcing decisions, and pricing negotiations across the OCD drug value chain

The cumulative impact of the United States tariffs introduced in 2025 is manifesting across multiple nodes of the obsessive-compulsive disorder drug value chain, forcing stakeholders to reassess supply resilience, cost structures, and sourcing strategies. Tariff-induced input cost pressures have particularly affected active pharmaceutical ingredients and certain specialized excipients, prompting manufacturers to evaluate alternative suppliers and production geographies to preserve margins while maintaining product quality. These adjustments have occurred alongside a broader industry trend toward dual sourcing and enhanced inventory buffering to mitigate future trade policy volatility.

Payers, procurement teams, and hospital formularies are responding by intensifying price negotiations and seeking contracting mechanisms that de-risk exposure to tariff-driven cost variability. Regulators and trade bodies have engaged in targeted dialogue to ensure continuity of critical medicines, and some firms have accelerated onshoring and regional manufacturing investments to circumvent duties and shorten lead times. The tariffs have also elevated the importance of transparent cost modeling and scenario planning, encouraging companies to incorporate trade policy risk into supply chain decisions and to explore strategic alliances that can absorb or offset tariff impacts while preserving patient access.

Strategic segmentation synthesis that maps drug classes, channels, formulations, and patient cohorts to differentiated commercial and clinical imperatives

A nuanced segmentation lens reveals the differentiated commercial dynamics that govern OCD pharmacotherapy demand, uptake, and competitive pressures. When examining drug class, major antidepressant categories including monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants each present distinct efficacy and tolerability profiles, with MAOIs further represented by phenelzine and tranylcypromine, SNRIs by desvenlafaxine, duloxetine, and venlafaxine, SSRIs by citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, and TCAs by amitriptyline, clomipramine, and imipramine; these therapeutic nuances influence prescribing patterns, switching behavior, and long-term adherence.

Distribution channel dynamics encompass hospital pharmacies, online pharmacies, and retail pharmacies, each serving different patient access needs and reimbursement pathways and shaping how products are merchandised and supported. Drug type segmentation across brand and generic markets drives pricing strategies, lifecycle management approaches, and commercialization investments. Route of administration-oral versus parenteral-affects formulation priorities, adherence support requirements, and clinical settings for administration. End-user distinctions among clinics, hospitals, and households reflect divergence in procurement cycles, care delivery models, and patient education imperatives. Finally, patient age group segmentation into adult and pediatric cohorts requires distinct safety considerations, dosing paradigms, and regulatory dossiers, making a tailored approach essential for clinical adoption and market penetration.

Actionable regional intelligence explaining how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics demand tailored commercialization and access strategies

Regional nuances materially affect how OCD pharmacotherapies are developed, reimbursed, and delivered, demanding geographically customized strategies. In the Americas, access frameworks, payer heterogeneity, and a robust private market shape commercialization tactics and prioritization of evidence generation that supports formulary inclusion and reimbursement. This region emphasizes outcomes-oriented contracting and real-world evidence to demonstrate value within diverse healthcare delivery models.

Europe, the Middle East & Africa present a mosaic of regulatory approaches and reimbursement environments, with pronounced differences between centralized regulatory pathways, national health technology assessment requirements, and emerging market constraints; companies must balance harmonized clinical data packages with localized health economic models. The Asia-Pacific region displays rapid adoption of digital health modalities and an expanding role of domestically manufactured generics and biosimilars, necessitating strategies that account for local manufacturing partnerships, variable payer coverage, and cultural dimensions of mental health care. Across all regions, evolving patient advocacy, telemedicine uptake, and regional manufacturing considerations inform differentiated market entry and scaling choices.

Insightful corporate behavior and competitive positioning analysis highlighting innovation, lifecycle management, and partnership strategies shaping OCD therapeutic portfolios

Competitive and corporate behavior within the obsessive-compulsive disorder drug space reflects a blend of innovation investment, lifecycle management, and partnerships to address access and differentiation. Organizations are increasing investment in late-stage clinical programs that seek improved efficacy or tolerability versus existing standards, while simultaneously optimizing portfolios through formulation improvements and extended-release or combination approaches. Research collaborations with academic centers and digital health vendors are becoming more common as companies pursue complementary nonpharmacologic solutions to enhance overall outcomes.

At the same time, generic entrants and established off-patent molecules exert pressure on pricing and reimbursement, compelling originators to emphasize brand value via outcomes data and support services. Strategic licensing, co-promotion, and regional manufacturing agreements are being used to accelerate distribution and reduce supply risk. Investor scrutiny around R&D productivity has prompted tighter prioritization of programs with clear clinical differentiation or regulatory incentives. Overall, corporate strategies are converging on a balanced mix of innovation, cost discipline, and partnership to sustain competitiveness while addressing payer and patient expectations.

Practical and high-leverage recommendations for executives to strengthen supply resilience, evidence generation, and value-driven commercialization in OCD therapeutics

Industry leaders seeking to strengthen their position in the OCD therapeutic domain should prioritize a set of pragmatic, high-impact actions that enhance resilience and commercial differentiation. First, align clinical development choices with payer evidence requirements by integrating health economics and outcomes research early in trial design to shorten the path to formulary acceptance. Simultaneously, fortify supply chains through regional diversification and strategic manufacturing agreements to reduce exposure to trade policy shocks and ensure continuity of supply.

Leaders should also invest in digital and patient-support services that improve adherence and real-world outcomes, thereby reinforcing product value propositions. Partnerships with behavioral health providers and telemedicine platforms can extend reach into under-served patient segments and create integrated care solutions. Finally, adopt dynamic pricing and contracting frameworks that reflect value delivered across varied care settings, and maintain an active watch on regulatory and reimbursement shifts to respond nimbly. Executing these coordinated moves will better position companies to deliver clinically meaningful innovations while safeguarding access and commercial viability.

Transparent, multi-method research approach integrating primary stakeholder interviews with systematic secondary evidence to deliver reliable, reproducible strategic insights

The research underpinning this executive analysis combines primary and secondary approaches to ensure robust, triangulated insights. Primary engagement included structured interviews with clinicians, payers, procurement officers, and manufacturing experts to capture operational realities, prescribing behavior, and access constraints across care settings. Secondary research entailed systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and publicly available safety reports to validate therapeutic trends and evidence gaps.

Analytical techniques integrated qualitative synthesis with quantitative trend analysis where appropriate, including time-series examination of regulatory filings, patent landscapes, and supply chain event histories. Cross-validation was achieved through subject matter expert consultations and scenario-based sensitivity checks to test assumptions about supply risk and policy impact. Ethical considerations and data provenance were maintained throughout the process, with a clear emphasis on transparency and reproducibility of methods to support confident decision-making by stakeholders.

Executive synthesis emphasizing the imperative to integrate clinical differentiation, supply resilience, and patient-centric strategies to achieve sustainable impact in OCD therapeutics

In conclusion, the contemporary OCD therapeutic environment is characterized by simultaneous pressures and opportunities across clinical, regulatory, and commercial dimensions. Advances in clinical understanding and the emergence of complementary digital interventions are opening pathways for improved patient outcomes, while trade policy shifts and intensified generic competition are reshaping cost and supply dynamics. Decision-makers must therefore integrate evidence generation, supply chain resilience, and patient-centric support services into cohesive strategies that reflect regional market realities and payer expectations.

By prioritizing differentiated clinical value, strengthening manufacturing and sourcing flexibility, and leveraging partnerships to extend care delivery, stakeholders can navigate policy volatility and competitive pressure while improving access for patients. The combined effect of these actions will determine which organizations can sustainably translate scientific progress into broad clinical impact and enduring commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rise of psychedelic-assisted therapies like psilocybin in clinical trials for treatment-resistant OCD
  • 5.2. Increased utilization of digital therapeutics and telepsychiatry platforms for remote OCD symptom management
  • 5.3. Advancements in precision medicine strategies using genetic biomarkers to predict OCD drug response
  • 5.4. Growing focus on glutamate-modulating agents as novel mechanisms of action in OCD treatment pipelines
  • 5.5. Expansion of real-world evidence and patient-reported outcome data influencing OCD drug reimbursement decisions
  • 5.6. Regulatory momentum for fast-track designations and orphan drug status in severe OCD therapeutic candidates
  • 5.7. Competitive pricing pressures driving development of generic and biosimilar alternatives to established SSRIs
  • 5.8. Rising investment in combination therapy trials pairing pharmacologics with cognitive behavioral interventions for OCD
  • 5.9. Emerging market expansion in Asia-Pacific and Latin America as new growth avenues for OCD therapeutics
  • 5.10. Pediatric and adolescent-focused OCD drug research accelerating child-specific formulation development and approval

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class

  • 8.1. MAOIs
    • 8.1.1. Phenelzine
    • 8.1.2. Tranylcypromine
  • 8.2. SNRIs
    • 8.2.1. Desvenlafaxine
    • 8.2.2. Duloxetine
    • 8.2.3. Venlafaxine
  • 8.3. SSRIs
    • 8.3.1. Citalopram
    • 8.3.2. Fluoxetine
    • 8.3.3. Fluvoxamine
    • 8.3.4. Paroxetine
    • 8.3.5. Sertraline
  • 8.4. TCAs
    • 8.4.1. Amitriptyline
    • 8.4.2. Clomipramine
    • 8.4.3. Imipramine

9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type

  • 10.1. Brand
  • 10.2. Generic

11. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Obsessive-Compulsive Disorder Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Households

13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Pediatric

14. Obsessive-Compulsive Disorder Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obsessive-Compulsive Disorder Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obsessive-Compulsive Disorder Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. Eli Lilly and Company
    • 17.3.3. GlaxoSmithKline plc
    • 17.3.4. H. Lundbeck A/S
    • 17.3.5. Teva Pharmaceutical Industries Ltd.
    • 17.3.6. Novartis AG
    • 17.3.7. Sun Pharmaceutical Industries Ltd.
    • 17.3.8. Viatris Inc.
    • 17.3.9. Otsuka Pharmaceutical Co., Ltd.
    • 17.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)

TABLE 28